Search

everythinglearnresearchcommunity

for

Search:↓

A user is considering an extensive hair loss treatment regimen including oral dutasteride, oral minoxidil, topical finasteride, tretinoin, microneedling, keto shampoo, laser comb, and PRP injections. Suggestions include simplifying the routine, possibly increasing minoxidil dosage, and considering alternatives like RU58841, while cautioning against using estrogen due to potential side effects.

Hair loss discussion includes treatments like Minoxidil, Finasteride, and RU58841. Users seek Alfatradiol sources and share personal experiences.

The user humorously describes trying various hair loss treatments, including minoxidil, finasteride, and RU58841, with a satirical twist involving psychedelic experiences and imaginary entities. They mistakenly used LSD instead of RU58841 and plan to continue experimenting with other substances.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Bayer dismissed HMI-115 due to focus shift away from women's health.

Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.

A British man's death at a Turkish hair transplant clinic raised safety concerns about such clinics. Users discussed risks of cheaper clinics and suggested alternatives like Thailand, Korea, and Colombia.

The conversation discusses using finasteride, dutasteride, RU58841, and testosterone to combat hair loss and block DHT, with some users expressing concerns about side effects and vegan options for medication. The discussion also touches on personal experiences with hormone treatments and the desire to maintain a youthful appearance.

A 22-year-old with advanced diffuse thinning is considering oral dutasteride after stopping finasteride due to side effects like brain fog and testicular pain. They are also contemplating a hair transplant combined with oral dutasteride and topical finasteride, noting a thick donor area.

Verteporfin is being explored for its potential to improve hair transplant outcomes by reducing scarring and increasing donor hair follicles. There is skepticism about the results, with some claiming misleading presentation of evidence.

A pharmacy error resulted in a finasteride solution being 100 times stronger than prescribed, not 10,000 times as initially feared. OP is advised to contact the pharmacy to clarify the preparation before traveling.

A user created a free AI-powered hair transplant simulator to help visualize post-transplant results, seeking feedback and offering it as a tool for clinics. Users discussed its usefulness, limitations, and the requirement for email and phone verification to prevent abuse.

A user is advocating for Phase 3 trials of the hair loss treatment PP405 to be conducted in Germany, citing benefits like a diverse patient base and faster access for European patients. Despite skepticism about the petition's influence, the user believes it can demonstrate significant interest and potentially influence strategic decisions.

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

The user has been using Dutasteride for over a year for hair loss and is considering a hair transplant if it doesn't work. Suggestions include adding Minoxidil and microneedling, but some advise against a transplant as the current treatment seems effective.

The user is seeking a knowledgeable trichologist or dermatologist in Belgium for a thorough scalp examination due to diffuse thinning and a previous diagnosis of male pattern baldness. They are interested in procedures like a trichogram and scalp biopsy.

A user shared their experience with two hair transplants in Istanbul, highlighting the importance of choosing clinics with a low doctor-to-patient ratio, ISHRS membership, thorough consultations, and reliable aftercare. They emphasized the significance of PRP shots post-procedure and advised careful selection of clinics, especially for crown procedures, due to limited donor area opportunities.

The post discusses a successful hair loss treatment involving a hair transplant, finasteride, and minoxidil. The user underwent a 2000 graft hair transplant at the hairline in a clinic in Sweden.

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.

The conversation is about someone experiencing hair regrowth using Minoxidil and Dutasteride, along with other treatments. They report their hairline is improving and their forehead appears smaller.

The conversation is about finding a source for RU58841 as a substitute for finasteride for hair loss treatment. Suggestions include Amazon and Anageninc.com.

The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It jokingly credits a person for the potential success of a treatment called GT20029.

People are discussing hair loss treatments and expressing hope for future hair cloning. Some mention using Minoxidil, finasteride, and RU58841.

A 15% discount is offered on hair research products like RU58841 and TEMPOL at Chemyo.com. The legality of selling these compounds is confirmed by the seller.

Scientists at UCLA have developed a promising treatment for male pattern baldness using a molecule called PP405, which can potentially stimulate dormant hair follicles. Initial trials showed significant results within a week, but larger clinical trials are needed to confirm its efficacy and safety.

The conversation discusses an all-in-one hair loss treatment combining minoxidil, azelaic acid, finasteride, and ketoconazole, aimed at addressing hair loss and scalp dandruff without drying out the hair. The user is considering this product to incorporate ketoconazole into their routine and start using minoxidil.

The user is concerned about hair loss and is using treatments like dutasteride, microneedling, and topical finasteride, while considering adding RU58841. They are also using Minoxidil on the temples and are worried about testosterone-related hair loss.

The conversation is about testing the effectiveness of RU58841 for hair loss, with the user planning to increase their dose to 30 mg per day along with 20 mg of Minoxidil. The test results showed approximately 70 mg/ml, which the user considers a good result.

Fo-Ti is discussed as a potential treatment for hair loss, but its effectiveness is questioned. Users express skepticism and caution about its use.

The conversation is about a user's hair loss treatment routine, which includes RU58841 for 9 months and Dutasteride for 6 months, with other unspecified treatments considered extra. One user inquired about the source of RU58841.

Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.